TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Red Cell Storage Duration Study
Brief Summary: The RECESS study will compare the effects of transfusing red blood cell units stored \<= 10 days vs. red blood cell units stored \>= 21 days, in patients who are undergoing complex cardiac surgery and are likely to need a red blood cell transfusion. The primary hypothesis is that there is a clinically important difference between the effects of shorter-storage red cell units and longer-storage red cell units on clinical outcomes and mortality risk.


Options:
A: Arm Label: Red blood cell transfusion; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Red blood cell transfusion
B: Arm Label: Single-Unit Blood Transfusion Protocol; Type: ACTIVE_COMPARATOR; Interventions: Biological: Blood Transfusion | Arm Label: Multiple-Unit Blood Transfusion Protocol; Type: ACTIVE_COMPARATOR; Interventions: Biological: Blood Transfusion | Intervention Type: BIOLOGICAL; Name: Blood Transfusion; Assigned to Arm(s): Multiple-Unit Blood Transfusion Protocol, Single-Unit Blood Transfusion Protocol
C: Arm Label: Liberal; Type: EXPERIMENTAL; Interventions: Drug: red blood cell transfusion trigger | Arm Label: Restrictive; Type: ACTIVE_COMPARATOR; Interventions: Drug: red blood cell transfusion trigger | Intervention Type: DRUG; Name: red blood cell transfusion trigger; Assigned to Arm(s): Liberal, Restrictive
D: Arm Label: Shorter-storage red blood cell units; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red blood cell units stored <= 10 days | Arm Label: Longer-storage red blood cell units; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red blood cell units stored >= 21 days | Intervention Type: BIOLOGICAL; Name: Red blood cell units stored <= 10 days; Assigned to Arm(s): Shorter-storage red blood cell units | Intervention Type: BIOLOGICAL; Name: Red blood cell units stored >= 21 days; Assigned to Arm(s): Longer-storage red blood cell units

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Red Cell Storage Duration Study
Brief Summary: The RECESS study will compare the effects of transfusing red blood cell units stored \<= 10 days vs. red blood cell units stored \>= 21 days, in patients who are undergoing complex cardiac surgery and are likely to need a red blood cell transfusion. The primary hypothesis is that there is a clinically important difference between the effects of shorter-storage red cell units and longer-storage red cell units on clinical outcomes and mortality risk.


Options:
A: Arm Label: Biological; Type: EXPERIMENTAL; Interventions: Biological: Transfusion | Arm Label: Standard PRBCs; Type: EXPERIMENTAL; Interventions: Biological: Transfusion | Intervention Type: BIOLOGICAL; Name: Transfusion; Assigned to Arm(s): Biological, Standard PRBCs
B: Intervention Type: PROCEDURE; Name: Red blood cell transfusion; Assigned to Arm(s): N/A
C: Arm Label: Shorter-storage red blood cell units; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red blood cell units stored <= 10 days | Arm Label: Longer-storage red blood cell units; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red blood cell units stored >= 21 days | Intervention Type: BIOLOGICAL; Name: Red blood cell units stored <= 10 days; Assigned to Arm(s): Shorter-storage red blood cell units | Intervention Type: BIOLOGICAL; Name: Red blood cell units stored >= 21 days; Assigned to Arm(s): Longer-storage red blood cell units
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Standard leukoreduced irradiated blood cell transfusion | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Biological: Washed leukoreduced irradiated blood cell transfusions | Intervention Type: BIOLOGICAL; Name: Standard leukoreduced irradiated blood cell transfusion; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Washed leukoreduced irradiated blood cell transfusions; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Red Cell Storage Duration Study
Brief Summary: The RECESS study will compare the effects of transfusing red blood cell units stored \<= 10 days vs. red blood cell units stored \>= 21 days, in patients who are undergoing complex cardiac surgery and are likely to need a red blood cell transfusion. The primary hypothesis is that there is a clinically important difference between the effects of shorter-storage red cell units and longer-storage red cell units on clinical outcomes and mortality risk.


Options:
A: Arm Label: Shorter-storage red blood cell units; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red blood cell units stored <= 10 days | Arm Label: Longer-storage red blood cell units; Type: ACTIVE_COMPARATOR; Interventions: Biological: Red blood cell units stored >= 21 days | Intervention Type: BIOLOGICAL; Name: Red blood cell units stored <= 10 days; Assigned to Arm(s): Shorter-storage red blood cell units | Intervention Type: BIOLOGICAL; Name: Red blood cell units stored >= 21 days; Assigned to Arm(s): Longer-storage red blood cell units
B: Arm Label: Restrictive Transfusion Policy; Type: ACTIVE_COMPARATOR; Interventions: Other: Restrictive transfusion policy | Arm Label: Liberal Transfusion Policy; Type: ACTIVE_COMPARATOR; Interventions: Other: Liberal Transfusion Policy | Intervention Type: OTHER; Name: Restrictive transfusion policy; Assigned to Arm(s): Restrictive Transfusion Policy | Intervention Type: OTHER; Name: Liberal Transfusion Policy; Assigned to Arm(s): Liberal Transfusion Policy
C: Arm Label: Epo1 and TT10; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Epo1 and TT7; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Epo2 and TT10; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Epo2 and TT7; Type: ACTIVE_COMPARATOR; Interventions: Drug: recombinant human erythropoietin, rhEpo | Arm Label: Placebo and TT10; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Placebo and TT7; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: recombinant human erythropoietin, rhEpo; Assigned to Arm(s): Epo1 and TT10, Epo1 and TT7, Epo2 and TT10, Epo2 and TT7 | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Placebo and TT10, Placebo and TT7
D: Arm Label: Allowed drop in hemoglobin to 4.5-5.5 mmol/L; Type: ACTIVE_COMPARATOR; Interventions: Other: Allowed drop in hemoglobin to 4.5-5.5 mmol/L | Arm Label: Allowed drop in hemoglobin to 5.6-6.5 mmol/L; Type: EXPERIMENTAL; Interventions: Other: Allowed drop in hemoglobin to level between 5.6-6.5 mmol/L | Intervention Type: OTHER; Name: Allowed drop in hemoglobin to 4.5-5.5 mmol/L; Assigned to Arm(s): Allowed drop in hemoglobin to 4.5-5.5 mmol/L | Intervention Type: OTHER; Name: Allowed drop in hemoglobin to level between 5.6-6.5 mmol/L; Assigned to Arm(s): Allowed drop in hemoglobin to 5.6-6.5 mmol/L

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparative Evaluation of the Effectiveness of 2 Available Resources in Estrie, for the Prevention of Type 2 Diabetes in High-risk Subjects
Brief Summary: This study compared the efficacy at one year of an interdisciplinary approach including individual counseling and group seminars versus group seminars alone to induce weight loss in subjects at high risk of developing type 2 diabetes.

This study also compare if a participant's presence in small informative meeting groups as the only form of intervention is sufficient to induce a lifestyle change, thus inducing the weight loss needed for the prevention of the diseases associated with obesity.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: interdisciplinary intervention or meeting-seminars | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: interdisciplinary intervention or meeting-seminars | Intervention Type: BEHAVIORAL; Name: interdisciplinary intervention or meeting-seminars; Assigned to Arm(s): 1, 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Falls Prevention | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Falls Prevention; Assigned to Arm(s): 1
C: Arm Label: physical activity and nutrition; Type: EXPERIMENTAL; Interventions: Behavioral: Project Fit | Intervention Type: BEHAVIORAL; Name: Project Fit; Assigned to Arm(s): physical activity and nutrition
D: Arm Label: Standard care; Type: EXPERIMENTAL; Interventions: Behavioral: Assertive Community Treatment (ACT) | Intervention Type: BEHAVIORAL; Name: Assertive Community Treatment (ACT); Assigned to Arm(s): Standard care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of an Integrated Obesity Management System on Patient's Care
Brief Summary: The investigators developed a program aimed at enhancing primary care physician (PCP) teams' expertise, self-efficacy and attitudes with respect to obesity management. The investigators implemented and evaluated this obesity management system based on a preceptorship combined with a virtual learning community favouring continuous support of family medicine groups (FMGs, Groupes de Médecine Familiale) by a team of experts in obesity management; significant improvements regarding their attitudes and perception of self-efficacy were observed immediately after the preceptorship and maintained after one year. Furthermore, the investigators observed significant changes in their practice that were maintained one year later.

The investigators hypothesize that their program combining preceptorships with a virtual community will improve: (1) management and weight loss of obese/overweight subjects who are treated by PCPs for hypertension (HTN), type 2 diabetes (DM2) or impaired glucose tolerance (IGT); and (2) screening and initial management of obesity among unselected patients of PCPs who practice in FMGs.


Options:
A: Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: group sessions, Drug: sibutramine, orlistat, diethylpropion, Behavioral: Low Calorie Diet, Health One, Other: Intensive Medical Combination Therapy for Obesity | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Control Condition | Intervention Type: BEHAVIORAL; Name: group sessions; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: sibutramine, orlistat, diethylpropion; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Low Calorie Diet, Health One; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Intensive Medical Combination Therapy for Obesity; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Control Condition; Assigned to Arm(s): 2
C: Arm Label: 5As Team Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: 5As Team Intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: 5As Team Intervention; Assigned to Arm(s): 5As Team Intervention
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Preceptorships; Type: EXPERIMENTAL; Interventions: Behavioral: 2-day preceptorship on obesity management | Intervention Type: BEHAVIORAL; Name: 2-day preceptorship on obesity management; Assigned to Arm(s): Preceptorships

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multisite Trial of ACQUIREc Therapy
Brief Summary: A multisite trial to testing different dosage levels of a systematic form of Pediatric Constraint-Induced (CI) Therapy called ACQUIREc Therapy. The high dosage treatment involved 6 hours of daily therapy services for 21 days. This was compared to a moderate dosage level of 3 hours of daily therapy services for 21 days. It was hypothesized that children receiving the higher therapy dosage would have greater and more clinically significant benefits from ACQUIREc Therapy but that both groups of children would benefit from the therapy services.


Options:
A: Intervention Type: BEHAVIORAL; Name: Soft Mitt Constraint Therapy for Sensory/Motor Impairment in Cerebral Palsy; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Pediatric Constraint-Induced Movement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Conventional pediatric motor rehabilitation therapy; Assigned to Arm(s): N/A
C: Arm Label: Treatment dosage levels examined; Type: EXPERIMENTAL; Interventions: Other: Therapy services (ACQUIREc Therapy) | Intervention Type: OTHER; Name: Therapy services (ACQUIREc Therapy); Assigned to Arm(s): Treatment dosage levels examined
D: Arm Label: Constraint-induced Movement Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Modified Constraint-induced Movement Therapy | Arm Label: Transditional rehabilitation; Type: OTHER; Interventions: Behavioral: Modified Constraint-induced Movement Therapy | Intervention Type: BEHAVIORAL; Name: Modified Constraint-induced Movement Therapy; Assigned to Arm(s): Constraint-induced Movement Therapy, Transditional rehabilitation

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Oral Misoprostol Titrated Solution Versus Vaginal Misoprostol for Induction of Labour: Randomized Controlled Trial
Brief Summary: The purpose of this study is to compare effectiveness and safety of an oral titrated solution of misoprostol with vaginal misoprostol for induction of labour with an alive fetus.


Options:
A: Arm Label: conventional oral misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Arm Label: titrated oral misoprostol; Type: EXPERIMENTAL; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): conventional oral misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): titrated oral misoprostol
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): 2
C: Arm Label: Oral Titrated Misoprostol Solution; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: Vaginal Misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Oral Titrated Misoprostol Solution | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Vaginal Misoprostol
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: misoprostol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): 1, 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Oral Misoprostol Titrated Solution Versus Vaginal Misoprostol for Induction of Labour: Randomized Controlled Trial
Brief Summary: The purpose of this study is to compare effectiveness and safety of an oral titrated solution of misoprostol with vaginal misoprostol for induction of labour with an alive fetus.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: misoprostol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): 1, 2
B: Arm Label: Oral Titrated Misoprostol Solution; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: Vaginal Misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Oral Titrated Misoprostol Solution | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Vaginal Misoprostol
C: Arm Label: Misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: Foley Catheter; Type: ACTIVE_COMPARATOR; Interventions: Device: Foley Catheter | Intervention Type: DEVICE; Name: Foley Catheter; Assigned to Arm(s): Foley Catheter | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol
D: Arm Label: conventional oral misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: misoprostol | Arm Label: titrated oral misoprostol; Type: EXPERIMENTAL; Interventions: Drug: misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): conventional oral misoprostol | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): titrated oral misoprostol

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Withdrawal Study to Evaluate the Safety and Efficacy of Delayed Release Rabeprazole in 1- to 11-Month-Old Pediatric Subjects With Symptomatic/Gastroesophageal Erosive Reflux Disease (GERD)
Brief Summary: The purpose of this study is to assess the effectiveness and safety of rabeprazole sodium, an inhibitor of gastric acid secretion of the protein pump inhibitor (PPI) class, compared with placebo in the treatment of gastrointestinal esophageal reflux disease (GERD) in infants 1 to 11 months of age.


Options:
A: Arm Label: Rabeprazole sodium 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Rabeprazole sodium 5 mg | Arm Label: Rabeprazole sodium 10 mg; Type: EXPERIMENTAL; Interventions: Drug: Rabeprazole sodium 10 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rabeprazole sodium 5 mg; Assigned to Arm(s): Rabeprazole sodium 5 mg | Intervention Type: DRUG; Name: Rabeprazole sodium 10 mg; Assigned to Arm(s): Rabeprazole sodium 10 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Oral omeprazole; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Rectal omeprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omeprazole rectally 1mg/kg | Intervention Type: DRUG; Name: Omeprazole rectally 1mg/kg; Assigned to Arm(s): Rectal omeprazole
C: Arm Label: Lansoprazole QD; Type: EXPERIMENTAL; Interventions: Drug: Lansoprazole microgranules suspension | Arm Label: Placebo QD; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lansoprazole microgranules suspension; Assigned to Arm(s): Lansoprazole QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo QD
D: Arm Label: Low dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: pantoprazole sodium enteric-coated spheroid suspension | Arm Label: High dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: pantoprazole sodium enteric-coated spheroid suspension | Intervention Type: DRUG; Name: pantoprazole sodium enteric-coated spheroid suspension; Assigned to Arm(s): High dose, Low dose

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women
Brief Summary: This study is an open-label, single site, randomized controlled trial comparing protease inhibitor (PI)-based antiretroviral therapy (ART) to non-PI based ART for HIV-infected pregnant and breastfeeding women of all CD4 cell counts at high risk of malaria. The study is designed to test the hypothesis that pregnant women receiving a PI-based ART regimen will have lower risk of placental malaria compared to pregnant women receiving a non-PI based ART regimen. The primary study endpoint of the study is placental malaria. This study also enrolls the infants of these women at the time of delivery.


Options:
A: Intervention Type: DIETARY_SUPPLEMENT; Name: No food supplement; Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Food supplement: fortified spread; Assigned to Arm(s): N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Food supplement: maize-soy flour; Assigned to Arm(s): N/A
B: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Drug: Lopinavir/ritonavir, Drug: Zidovudine, Drug: Lamivudine | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Efavirenz, Drug: Zidovudine, Drug: Lamivudine | Intervention Type: DRUG; Name: Lopinavir/ritonavir; Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: Efavirenz; Assigned to Arm(s): Group B | Intervention Type: DRUG; Name: Zidovudine; Assigned to Arm(s): Group A, Group B | Intervention Type: DRUG; Name: Lamivudine; Assigned to Arm(s): Group A, Group B
C: N/A
D: Arm Label: MSPP Integrated Package; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Nutributter 3 Months, Integrated Package; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Nutributter Program, Other: Integrated Package | Arm Label: Nutributter 6 Months, Integrated Package; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Nutributter Program, Other: Integrated Package | Intervention Type: DIETARY_SUPPLEMENT; Name: Nutributter Program; Assigned to Arm(s): Nutributter 3 Months, Integrated Package, Nutributter 6 Months, Integrated Package | Intervention Type: OTHER; Name: Integrated Package; Assigned to Arm(s): Nutributter 3 Months, Integrated Package, Nutributter 6 Months, Integrated Package

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of an Active Strategy to Implement the Canadian CT Head Rule: Phase III
Brief Summary: Each year, Canadian emergency department physicians treat 600,000 patients with head injury. Many of these are adults with "minor head injury", i.e. loss of consciousness or amnesia and a Glasgow Coma Scale (GCS) score of 13-15. Only 6.2% of these "minor" patients have some acute injury on computed tomography (CT scan) and only 0.5% have an epidural hematoma requiring surgery. Among Canadian teaching hospital emergency departments, we have shown a fourfold variation in use of CT and that a small but important number of intracranial hematomas are missed at the first visit.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Early Intervention | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Delayed intervention | Intervention Type: BEHAVIORAL; Name: Early Intervention; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Delayed intervention; Assigned to Arm(s): 2
B: Intervention Type: BEHAVIORAL; Name: Opinion Leaders, Academic Detailing, Reminders, and Feedback; Assigned to Arm(s): N/A
C: Intervention Type: PROCEDURE; Name: CT Scan; Assigned to Arm(s): N/A
D: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Educational Reminder | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Educational Reminder | Intervention Type: BEHAVIORAL; Name: Educational Reminder; Assigned to Arm(s): Control, Intervention

Answer: C